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Objective: To construct an updated comorbidity index (Patient Register Index [PRI]) using 
national data collections from Norway and compare its predictive ability of 1-year mortality 
with the Charlson Comorbidity Index (CCI).
Materials and methods: Data regarding over 1.11 million patients registered in the Norwegian 
Patient Register in 2010 and 2011 were used to construct the PRI. The PRI was evaluated by 
comparing its model fit and discrimination with the CCI.
Results: Compared with the CCI, the PRI weights decreased for six, increased for four, and 
were unchanged for seven diseases. When the PRI was added to the model including age and 
sex, the age effects were reduced by up to 38% for patients older than 50 years. All measures 
of model fit improved for the PRI model.
Conclusion: Adjustment for comorbidity is especially important for patients 50 years of 
age or older, and its effect on 1-year mortality is almost comparable to the age effect. The 
PRI is based on more recent data than the CCI, and is more representative of the general 
population due to its construction.
Keywords: comorbidity, National Patient Register, Charlson Comorbidity Index, predictive 
ability, patient-register index, prognostic value
Introduction
Comorbidities are defined as diseases that are concomitant to the disease under 
study.1 When survival in medical and epidemiological research is studied, it is impor-
tant to consider the effect of comorbidity, as it could be a potential confounder or 
an effect modifier for other prognostic factors.2–6
The Charlson Comorbidity Index (CCI) and the Elixhauser method are the most 
commonly used methods to assess comorbidity.7,8 The CCI is used more often, is less 
complex than the Elixhauser method, and was therefore chosen as the reference 
index in the present study. The CCI was originally developed based on data from 
all patients admitted to the New York Hospital–Cornell Medical Center during a 
1-month period in 1984, with the objective of predicting 1-year mortality. The risk 
of death associated with each of the 19 predefined diseases included in the CCI 
was expressed as weights with values of 1, 2, 3, or 6. Summing the weights for all 
contributing diseases gives the CCI score for each patient. The CCI was validated 
using an external cohort consisting of 685 breast cancer patients receiving their 
first treatment in 1962–1969 at Yale New Haven Hospital.7
The original CCI has been modified and evaluated by many authors.9–13 Quan 
et al developed coding algorithms for constructing the CCI based on the codes of the 
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Tenth Revision of the International Classification of Diseases 
(ICD-10).14 Sundararajan et al assessed that the version of 
the CCI created by Quan et al outperformed all the other ver-
sions they considered, though all of the ICD-10 versions of 
the Charlson algorithm performed satisfactorily.15 However, a 
persistent challenge for researchers who wish to use the CCI is 
that the data set of interest may not contain sufficient medical 
information to assess all the diseases included in the index. 
One source of such information in many countries is national 
patient registers. These are based on hospital administrative 
databases, from which data are often readily available.
Due to better treatment and technological improvements, 
a patient’s risk of death has reduced since the CCI was estab-
lished in the 1980s, and the index has been updated accord-
ingly. Bottle and Aylin12 and Quan et al both updated the 
CCI.11 Bottle and Aylin used national data from the UK and 
studied in-hospital mortality, while Quan et al used regional 
data from the Calgary Health Region of Canada to study 
1-year case fatality. However, to our knowledge, no previous 
study has combined the use of national patient-register data 
and death within 1 year as the study end point.
The aim of the present study was to evaluate the impor-
tance of including a comorbidity measure into analyses 
when predicting 1-year mortality using data from the 
Norwegian Patient Register (NPR). A second aim was to 
construct a modified version of the CCI that can be used 
with patient-register data (the Patient Register Index, PRI), 
and compare the predictive ability of the CCI and the PRI, 
as well as the confounding effect of each index on age. 
An additional aim was to describe the pattern of diseases 
included in the CCI by age and sex, based on data from all 
hospitals in Norway registered in the NPR.
Materials and methods
The nPr
The NPR is a national health register covering all sectors 
of the specialized health care services. Reporting to NPR is 
mandatory, and the register includes data on all patients 
treated in Norwegian government-funded hospitals. 
Personal identification numbers have been reported to 
the NPR from 2008 onwards. This enables researchers and 
policy makers to follow the disease trajectory of patients 
between sectors and hospitals. Also, alignment of data 
and validation with other national health registries is 
made feasible.
The study sample was selected from the NPR data reported 
from all hospitals, which consisted of three main data sources 
for statistics. The first source was visits for medical treatment 
for in- and outpatients at publicly financed hospitals. The two 
other sources were private hospitals and private specialist 
practices. The government purchases medical treatment from 
private hospitals and specialists practices as a supplement to 
services at the public hospitals. The NPR does not include 
data on privately financed hospital treatments.
The basic data unit in the NPR is hospital visits.  However, 
when a patient is transferred between wards at the same 
hospital, the record is aggregated. Each episode of national 
hospital data contains one or more diagnoses, coded accord-
ing to the ICD-10.
study sample
To provide information on the total disease history of the 
patient, the personal identification number was used to link 
episodes of treatment registered at different hospitals, sectors, 
and years. Initially, all patients in the NPR registered with 
a hospital visit in 2010 or 2011 were identified, constituting 
15,214,796 visits. Figure 1 shows an overview of exclu-
sions of patient visits in the study. Three subgroups of the 
initial data suffered from incomplete reporting of personal 
identification numbers. The first group was outpatients at 
private specialist practices in 2010 and 2011 (3,359,618 
visits). The reason for incomplete reporting in this group was 
mainly related to technical limitations in their information-
technology systems. To avoid any selection bias, we then 
also excluded 10,131,791 outpatient visits registered at 
publicly financed hospitals. However, we decided to keep 
15,214,796 patient visits
1,584,191 not newborn
visits
49,249 visits without
person identification
number excluded
139,196 newborn visits
excluded
3,359,618 (outpatient visits from
private specialist practices) +
10,131,791 (outpatient visits
from publicly financed hospitals)
excluded
1,534,942 visits with
personal identification
number
1,723,387 inpatient visits
Figure 1 Flowchart shows the included and excluded patients in the study 
population.
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outpatient visits with surgical procedure codes, because this 
activity mainly is performed at publicly financed hospitals 
or publicly financed private hospitals. The second group of 
visits excluded due to incomplete reporting were data on 
newborn babies (139,196 visits), since a large proportion 
had not yet received a personal identification number at the 
time of registration. The third group was any other patient 
visits that were lacking a correctly reported personal identi-
fication number (49,249 visits). After these exclusions, the 
data were aggregated, resulting in 1,534,942 eligible visits, 
corresponding to 1,113,341 unique patients.
The first hospital visit during the study period was 
defined as the patient’s index visit. The end of follow-up 
was defined as the date of death if the patient died within 
1 year of the index visit, or the date 1 year after the index 
visit (censoring date). Sex, age category, and ICD-10 codes 
(truncated to three digits for the index visit) were obtained 
from the NPR. To avoid the possibility of tracing back to 
individual patients, we received age information in 5-year 
age-group categories. Duration in days from the index visit 
to end of follow-up, vital status, and history of the diseases 
(dichotomous variables) included in the CCI that were listed 
up to 1 year prior to the index visit were obtained from the 
NPR. The NPR routinely obtains information on vital status 
and date of death from the National Population Register.16 
The data file obtained from the NPR was anonymized, 
and thus no requirement for regulatory ethical approval in 
Norway was needed.
The original CCI included 19 diseases, but for the 
purposes of the present study, leukemia and lymphoma 
were included in the disease category “any malignancy”, 
as done by other authors.9–11 These 17 CCI diseases were 
identified by the ICD-10 coding defined by Quan et al 
in 2005.14 A primary diagnostic code is the code for the 
main medical condition causing the admission. Secondary 
diagnostic codes are codes for diseases that exist at the 
same time as the primary disease, or diseases that develop 
and need examination or treatment during the admission. 
Information from both primary and secondary diagnostic 
codes was obtained for each patient.
statistical analysis
The PRI weights were estimated using a Cox regression 
model of time from index visit to death with follow-up 
censored at 1 year, adjusted for sex, 5-year age categories 
(0–4 years … 95+ years) and 17 CCI disease indicators. 
An algebraically correct method was used to define new 
weights for the CCI diseases by summing the regression 
coefficients, not the hazard ratios (HRs).17 The PRI was 
constructed by multiplying the regression coefficients 
by a scaling constant – k, then rounding it to the nearest 
integer, and finally summing it over all the CCI diseases. 
The scaling constant k was chosen such that the maximum 
weight for a specific disease in the PRI became the same 
integer as the maximum weight in the CCI, and thus k 
was set to 2.3.
Both the construction and comparison of the PRI and the 
CCI were done through an internal tenfold cross-validation 
procedure.18 Ten subsets of the data were randomly defined, 
and nine of them were used to develop the PRI, with the last 
subset used to run the comparison. This was done for all ten 
subsets, and the results are given as the mean values from the 
ten runs. To predict 1-year mortality, three logistic regression 
models were fitted, one including sex and age (base model), 
one including sex, age, and the CCI (CCI model), and one 
model including sex, age, and the PRI (PRI model).
Model fit was compared using several measures of global 
fit. The Bayesian information criterion (BIC) is a likelihood-
based measure, and for model fit, the lower the BIC-value, 
the better the fit.19 Likelihood ratio chi-square statistics were 
also used to test model fit. McFadden’s R2 is a measure of 
improvement in fit over the intercept model.20 The Brier score 
was used to directly compare the observed outcomes with the 
predicted probabilities.19 The C-statistic, which is a summary 
of a model’s ability to discriminate between those who do and 
those who do not experience the outcome, was calculated for 
each model.21 This measure is the most commonly used in 
the medical and epidemiological literature when comparing 
different comorbidity indices.11,13,15,22,23 The C-statistic varies 
from 0.5, which indicates that the discrimination is due to 
chance alone, to 1, which indicates perfect discrimination. 
The general classification of discrimination is “acceptable” 
(c ∈ [0.7, 0.8]), “excellent” (c ∈ [0.8, 0.9]), and “outstanding” 
(c ∈ [0.9, 1]).24 To assess which index changed the predicted 
value most when added to the base model, movement from 
the estimated probabilities of the outcome were compared. 
This was done using the net reclassification improvement 
(NRI), which is defined as the difference in proportions mov-
ing up or down in risk among patients who died and those 
who survived. We also used the integrated discrimination 
improvement (IDI), which measures the difference in the 
mean predicted probabilities between those who died and 
those who did not in the CCI and PRI models compared 
to the base model.25,26 We also calculated how much the 
 probabilities changed on average when a comorbidity index 
was included in the model:
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(1)
This quantifies the effect of introducing a comorbidity 
index into a model. To compare the importance of includ-
ing age, sex, and a comorbidity index in the model, ∆pˆ 
was calculated with and without each of the variables in a 
subanalysis with patients aged over 50 years who were not 
admitted to hospital due to any of the 17 CCI diseases at the 
index visit.
In the description of the disease pattern, the patient 
group was age-standardized according to the Norwegian 
standard population in 2011.27 All analyses were done using 
Stata 13.28
Results
The majority of the 1,113,341 patients in the study were 
women (57.0%). For 68.1% of the patients, the index visit 
was a hospitalization. Figure 2 presents the proportion of 
the Norwegian population with one or more of the CCI 
diseases in 2010–2011 and the total proportion admitted 
to Norwegian hospitals in that same period. Twenty-two 
percent of the patients were registered with at least one CCI 
disease, but among men and women below 50 years of age, 
the proportion was less than 3%. For patients 50 years of 
age or older, the proportion with CCI diseases increased 
with age, and the increase was more prominent among 
men. For both sexes, there was a strikingly high propor-
tion of hospital admission in the youngest age-group (0–4 
years). This was mostly due to diseases of the respiratory 
system (data not shown). For women, there was a peak 
around 30–34 years (Figure 2) as a result of birth-related 
admissions (data not shown). There was a small peak for 
men aged 20–24 years as well, which was mostly attrib-
uted to ICD-10 codes within S00-T98 (“Injury, poisoning, 
and certain other consequences of external causes”, data 
not shown).
The age-standardized proportions of the Norwegian 
population with each of the CCI diseases are shown in 
Figure 3. The five most common CCI diseases for men 
and women were myocardial infarction, cerebrovascular 
disease, chronic pulmonary disease, diabetes without 
chronic complications, and malignancies, but the order of 
importance differed.
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Figure 2 Total proportion of the norwegian population admitted to hospitals in 2010–2011 in norway or with a condition included in the Charlson Comorbidity index 
(CCi) present within the previous year, by sex and age-group.
Notes: Data shown are for (A) women and (B) men.
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The overall proportion of deceased patients within 1 year 
was 4.8% (52,938 patients), and the 1-year risk of death was 
significantly higher for patients with at least one CCI disease 
compared to those with none (HR 4.5, confidence interval 
4.4–4.6) (Table 1). The proportion of patients with each CCI 
disease ranged between 0.05% (acquired immunodeficiency 
syndrome [AIDS]/human immunodeficiency virus [HIV]) 
and 4.9% (chronic obstructive pulmonary disease [COPD]). 
Metastatic tumor was associated with the highest hazard, 
while rheumatic diseases and diabetes without chronic com-
plications were associated with the lowest hazard for 1-year 
mortality. Across all CCI diseases, the mean CCI score was 
0.4, the median number of diseases present in the patients 
was 0, and the range was 0–8.
When the weights for the CCI diseases in the PRI were 
compared with those in the CCI, the weights for seven 
diseases remained unchanged, four increased in magni-
tude, and six decreased in magnitude. Except for two CCI 
diseases – moderate-to-severe liver disease and AIDS/
HIV – the weights in the PRI only deviated by one if at all 
compared to those in the CCI. The maximum observed 
CCI and PRI values among the patients were 12 and 15, 
respectively. The overall mean CCI was approximately equal 
to the mean PRI (0.43 versus 0.42).
Table 2 presents the measures of model fit obtained from 
the internal cross-validation for the three prediction models. 
The C-statistic was marginally better for the PRI model than 
for the CCI model (91.5 versus 91.3). All measures showed 
improvement in fit when the PRI was included in the model 
instead of the CCI (Table 2).
Among patients aged 50 years or older who were not 
admitted to hospital due to any of the 17 CCI diseases, the 
ten most common categories for admission are listed in 
Table 3. ICD-10 code H25, “Senile cataract” (4.2%), and 
R07, “Pain in throat and chest” (3.0%), were the two most 
common conditions. The rest contributed with less than 3% 
each. Figure 4 shows the change in the effect of age when 
either of the two comorbidity indices was added to the base 
model for these patients. Including the PRI in the model led 
to a reduction in the effect of age for all age-groups, ranging 
from 3.5% in the 55–59-year group to 38% in the 95+ year 
group. This reduction was greater than the reduction observed 
for the CCI model.
Using backward elimination from the PRI model for 
patients 50 years of age or older with an index visit that was 
not due to a CCI disease, the change in the estimated prob-
ability (∆pˆ) was 2.8%, 4.3%, and 0.7% when the PRI, age, 
and sex were removed, respectively. Similarly, for the CCI 
0 0.25 0.5 0.75 1 1.25 1.5
Percent
AIDS/HIV
Metastatic solid tumor
Mod/severe liver dis
Any malignancy
Renal dis
Hemiplegia or paraplegia
Diabetes with chr compl
Diabetes without chr compl
Mild liver dis
Peptic ulcer dis
Rheumatic dis
Chr obstructive pulmonary dis
Dementia
Cerebrovascular dis
Peripheral vascular dis
Congestive heart failure
Myocardial infarction
Women
Men
Figure 3 age-standardized proportion (%) of the norwegian population admitted to hospitals in 2010–2011 in norway with any of the 17 conditions in the Charlson 
Comorbidity index present within the last year, by sex.
Abbreviations: dis, disease; chr, chronic; compl, complications; mod, moderate; AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus.
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Table 1 number and proportion of patients (present and dead) with Charlson Comorbidity index (CCi) diseases (not mutually 
exclusive) registered in the norwegian Patient register between January 1, 2010 and December 31, 2011 
Comorbidity Number  
of patients
Proportion with  
comorbidity (%)
Number 
dead
Proportion  
dead (%)
HR 95% CI CCI PRI
no 861,553 77.4 12,296 1.4 1.0 – 0 0
Yes 251,788 22.6 40,642 16.1 4.46 4.36–4.55 .0 .0
Total 1,113,341 100.0 52,938 4.8     
Type of comorbidity         
no chr dis 861,553 77.4 12,296 1.4 1.0 – 0 0
Myocardial infarction 44,034 4.0 7,741 17.6 1.25 1.22–1.28 1 1
Congestive heart failure 32,408 2.9 9,745 30.1 2.07 2.02–2.12 1 2
Peripheral vascular dis 18,459 1.7 3,253 17.6 1.36 1.31–1.41 1 1
Cerebrovascular dis 42,425 3.8 7,446 17.6 1.56 1.52–1.60 1 1
Dementia 15,225 1.4 5,391 35.4 2.34 2.27–2.41 1 2
Chronic pulmonary dis 54,410 4.9 7,769 14.3 1.65 1.60–1.69 1 1
rheumatic dis 14,110 1.3 1,261 8.9 1.03 0.97–1.09 1 0
Peptic ulcer dis 5,408 0.5 931 17.2 1.45 1.36–1.55 1 1
Mild liver dis 6,007 0.5 496 8.3 2.72 2.49–2.98 1 2
Diabetes without chr compl 38,237 3.4 4,654 12.2 1.20 1.17–1.24 1 0
Diabetes with chr compl 8,558 0.8 1,421 16.6 1.44 1.36–1.52 2 1
hemiplegia or paraplegia 3,265 0.3 224 6.9 1.60 1.40–1.83 2 1
renal dis 3,905 0.4 536 13.7 1.67 1.54–1.82 2 1
any malignancy 42,667 3.8 7,564 17.7 2.94 2.86–3.01 2 2
Mod or severe liver dis 1,184 0.1 390 32.9 7.47 6.67–8.27 3 5
Metastatic solid tumor 14,917 1.3 7,777 52.1 13.80 13.46–14.15 6 6
AIDS/HIV 536 0.05 31 5.8 3.61 2.53–5.14 6 3
Notes: Hazard ratios (HRs) for 1-year mortality, and 95% confidence intervals (CIs), adjusted for age and sex, together with weights for both the CCI and Patient Register 
index (Pri), are shown.
Abbreviations: AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus; dis, disease; chr, chronic; compl, complications; mod, moderate.
model, ∆pˆ was 2.6%, 4.7%, and 0.7% when the CCI, age, 
and sex were removed, respectively.
Discussion
We observed that for patients 50 years of age or older, comor-
bidity based on NPR data was almost equally important as age 
for predicting 1-year mortality. Measured by the proportion 
of the Norwegian population with a CCI disease registered 
in the NPR, the disease burden increased with age, reaching 
52% and 38% in the oldest age-group for men and women, 
respectively. The weights for four CCI diseases were higher 
in the PRI compared to the corresponding weights in the 
CCI, while the weights for six diseases were lower in the 
PRI than in the CCI.
The PRI was marginally better than the CCI in predicting 
1-year mortality. The C-statistics showed that the performance 
of both indices was rated as “outstanding” in discriminating, 
according to the standard C-statistic  classification, between 
those who died and those who did not.24 The base model pro-
duced a C-statistic of 0.869, while the C-statistic increased to 
0.913 and 0.915 when the CCI and the PRI were included in 
the model, respectively. Therefore, the majority of the abil-
ity to discriminate came from sex and age, but both of the 
indices increased the discrimination ability further, which is 
in agreement with the findings of Gabbe et al29 and Kilgore 
et al.30 For patients over 50 years of age, we observed that 
the PRI was almost as important as age, while the CCI was 
relatively less important than the PRI. In addition, a reduction 
in the effect of age for those over 50 years of age increased 
with age toward 38% when the PRI was added to the base 
model, showing the importance of including information 
regarding comorbidity when predicting the probability of 
death, especially in elderly patients.
The lack of data from privately financed hospitals could 
cause concern of possible introduced bias. However, in 2008 
the total use of privately financed hospitals in Norway was 
approximately 0.5% of the total health care service.31,32 
Therefore, excluding these patients would probably not 
have induced any major bias. Further, we only included 
inpatients and those outpatients with a surgical procedure 
code. The exclusion of all the outpatient visits with only 
medical procedures or no procedures at all probably led to an 
underestimation of the prevalence of the least severe diseases 
(those who did not need a hospitalization). The main aim 
in this study, however, was not to estimate the prevalence 
of a disease, but to construct a valid modification of the 
CCI. The private specialist practices are not situated evenly 
throughout the country. If we had included all outpatient 
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issues, explaining why the numbers in the NPR from 2010 to 
2011 are lower than the corresponding published prevalence 
estimates.33,34 Bakken et al showed good agreement between 
the data included in the NPR and the Cancer Registry of 
Norway.36 It is reasonable to believe that the patients we 
identified in the NPR had more severe disease and thus poorer 
prognosis than those suffering from the same diseases, but 
not admitted to hospital.
The uniqueness of this study is that we used two alter-
native methods (NRI and IDI) for comparing the quality 
of the reclassification of patients. None of the previous 
papers describing modifications of a comorbidity index 
has to our knowledge used these predictive probability 
measures. The NRI was 74.5% and 84.0% for the CCI and 
PRI, respectively, showing that inclusion of a comorbidity 
index increased the credibility of a model’s predictive abil-
ity, and the model including the PRI correctly determined 
the risk of a larger proportion of patients. Also, here the 
model including the PRI yielded a higher IDI of 10.7% 
compared to 9.9% for the model that included the CCI. 
Therefore, the PRI model has a better ability to reclas-
sify patients than the CCI model. In addition, our defined 
∆pˆ illustrated the importance of including a comorbidity 
Table 3 number and proportion of patients aged 50 years 
or older not admitted to hospital for any of the 17 Charlson 
Comorbidity index diseases
ICD-10 Classification Number Proportion (%)
M00-M99 Diseases of the 
musculoskeletal system  
and connective tissue
75,156 17.0
 
s00-T98 injury, poisoning, and  
certain other consequences  
of external causes
57,379 13.0
 
i00-i99 Diseases of the  
circulatory system
46,757 10.6
r00-r99 symptoms, signs, and 
abnormal clinical and 
laboratory findings not 
elsewhere classified
39,821 9.0
 
K00-K93 Diseases of the digestive  
system
37,648 8.5
h00-h59 Diseases of the eye and 
adnexa
35,662 8.1
n00-n99 Diseases of the  
genitourinary system
35,563 8.0
J00-J99 Diseases of the respiratory  
system
26,589 6.0
C00-D48 neoplasms 20,293 4.6
g00-g99 Diseases of the nervous  
system
19,138 4.3
 Other 48,742 11.0
 Total 442,748 100.0
Abbreviation: ICD-10, Tenth Revision of the International Classification of Diseases.
Table 2 Global measures of model fit, discrimination, and 
calibration statistics
Model evaluation 
measures
Base CCI  
model
PRI 
model
Global measures
lr χ2 10,556 14,623 14,834
P-value* ,0.01 ,0.01 ,0.01
BiC 32,269 28,213 28,003
R2 (%) 24.8% 34.3% 34.8%
Brier (%) 3.9% 3.5% 3.5%
Discrimination
C-index (%) 86.9% 91.3% 91.5%
nri (%) – 74.5% 84.0%
iDi (%) – 9.9% 10.7%
ˆ∆p† – 2.6% 2.8%
Notes: Models include the base model with sex and age, the model including sex, 
age, and Charlson Comorbidity index (CCi), and the model including sex, age, and 
the Patient register index (Pri), using an internal tenfold cross-validation procedure. 
*P-value for lr test between the base model and a model including CCi or Pri; 
†
=
∆ = ∑ −ˆ ˆ ˆ .
n
i 1
1
age, sex, comorbidity, iage, sex, in
P p p
Abbreviations: lr, likelihood ratio; BiC, Bayesian information criterion; nri, net 
reclassification improvement; IDI, integrated discrimination improvement.
visits, this would have introduced a possible regional bias 
using the PRI.
The Norwegian Prescription Database reported that 
approximately 156,000 (3.1%) of Norwegians used medica-
tion for diabetes in 2011. The total prevalence of diabetes in 
Norway is uncertain. In addition to those using medications, 
there is an unknown number of patients with type 2 diabetes 
who are managed through lifestyle changes only. However, 
a Norwegian study reported that 4.3% of the population suf-
fered from diabetes in the period 2006–2008.33 In our data, 
we identified approximately 47,000 cases of diabetes treated 
in hospitals during the study period (1% of the Norwegian 
population). The Norwegian Institute of Public Health has 
reported that the prevalence of COPD in Norway is around 
200,000 (4%).34 In our study, 54,410 patients admitted to 
hospital in 2010–2011 were either treated for COPD or had it 
registered in their disease history. Lastly, the Cancer Registry 
of Norway reported a cancer prevalence of 215,000 in 2011.35 
The observed prevalence from the NPR is measured using a 
combination of prevalence and incidence, since it includes 
patients with either a newly diagnosed cancer or a  diagnosis 
in the past in continuous need of treatment.  However, con-
sidering any malignancy and metastatic tumor as one group 
in the NPR data, there were 57,584 cancer patients. Many 
patients with COPD and cancer do not need an annual or 
biannual consultation at a hospital, either because they are 
well controlled or considered cured from their disease, or 
since their assigned general practitioner handles regular 
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index in a model, as opposed to using the base model, in 
predicting the 1-year mortality for patients 50 years of 
age or older.
The present study is closely related to the work done by 
Quan et al and Bottle and Aylin.11,12 Quan et al developed an 
updated version of the CCI based on the population of Calgary, 
Canada, and validated it using data from six different nations. 
A major advantage of the study of Quan et al was that they 
validated their updated index externally, in addition to being 
population-based. The advantage of Bottle and Aylin’s study 
was that they developed new empirical weights based on 
English administrative data in 2007–2008 (with over 5 million 
records). However, they studied in-hospital mortality only, 
as individual follow-up was not possible. Our proposed PRI 
is based on much larger patient numbers than Quan et al’s, 
and more complete follow-up after discharge from hospital 
compared with that of Bottle and Aylin, which is very impor-
tant, especially considering that only 35% of the deceased in 
Norway in 2011 died in hospitals.37
When constructing the PRI, diagnoses of the CCI dis-
eases, recorded both in primary and secondary fields from 
the index visit as well as the history, and recorded up to 
1 year prior to the index visit were included. The rationale 
behind this was that such an index should be based on the 
most recent disease history available. Pine et al and Ghali 
et al both showed improved discrimination when conditions 
present upon admission were included.38,39 In all subanalyses 
for patients 50 years of age or older, we excluded data for 
the patients who were admitted to hospital due to any of the 
17 CCI diseases. The rationale behind this was that patients 
under 50 years of age have a low presence of comorbidities. 
In addition, we wanted to study comorbidity – diseases in 
addition to the one causing the index visit – and not morbid-
ity. This study design is similar to the situation researchers 
meet when they want to add comorbidity information to 
their study cohort.
One limitation of our study was that we were not able 
to validate the PRI using external data. Another  limitation 
regards the inclusion criteria of patients: we excluded 
outpatients registered with only medical procedures or no 
procedures at all. This excluded many patients and limits the 
generalizability of the results, but it was necessary due to the 
large variation regarding the degree of reported personal iden-
tification numbers from private specialist practices.  Outpatient 
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Figure 4 The age effects (hazard ratios) relative to the age-group 50–54 years (log scale), for different models based on patients not admitted for any of the 17 Charlson 
Comorbidity index (CCi) diseases registered in the norwegian Patient register in 2010–2011.
Abbreviation: Pri, Patient register index.
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consultations are usually scheduled for patients with chronic 
and non-life-threatening diseases, such as dementia, rheu-
matism, and diabetes; hence, there is a considerable risk of 
underestimating the number of patients suffering from these 
diseases in our study. On the other hand, the strengths of the 
study are that in contrast to the CCI, the PRI was developed 
using data from a national register. Secondly, the algebraically 
correct method of the CCI was used when developing the 
PRI.17 Finally, the large sample size and access to complete 
mortality data are obvious strengths.
Conclusion
It is of high importance to include a comorbidity index in 
observational studies of disease prognosis, especially in 
elderly patients. Both the CCI and the PRI showed a high 
degree of discrimination, indicating that both have good 
predictive ability. However, the PRI explained a larger propor-
tion of the observed effect of age, and the PRI weights reflect 
the patterns in the data from the NPR. We have shown that 
weighting the CCI for a specific population slightly improves 
the performance of the CCI. The PRI is by its construction 
more representative of the general population, and can be 
generalized to other countries in situations where data from 
a national patient register are used.
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